This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Necuparanib

Momenta Pharmaceuticals, Inc.

Drug Names(s): M402

Description: M402 is a heparan sulfate glycosaminoglycan (HSGAG) mimetic engineered from low molecular weight heparin (LMWH) to have potent anti-metastatic properties and low anticoagulant activity. M402 binds and inhibits multiple factors including VEGF, FGF2, SDF-1-alpha, P-selectin, and heparanase.

HSGAGs are complex sugar-based molecules present in the tumor microenvironment that present growth factors, cytokines, and chemokines necessary for tumor cell growth, migration, and survival; M402 is designed to exploit the biology of HSGAGs.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug